/

Empresas

H.

No verificado

H. Lundbeck A/S

Sobre qué escribimos

BiologíaEconomíaFarmacéuticaSanidadStart-up

7 Comunicados de prensa

Ver todos los comunicados de prensa

08/05/2025

Farmacéutica

Sanidad

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Fuente

H. Lundbeck A/S

Editor

1.00

0

06/05/2025

Farmacéutica

Tecnología de la información

Telecomunicaciones

Sanidad

Economía

Patentes, marcas y derechos de autor

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer

Fuente

H. Lundbeck A/S

Editor

1.00

0

04/04/2025

Farmacéutica

Sanidad

Finanzas

Biología

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Fuente

H. Lundbeck A/S

Editor

1.00

0

31/03/2025

Farmacéutica

Sanidad

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Fuente

H. Lundbeck A/S

Editor

1.00

0

26/03/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office

Fuente

H. Lundbeck A/S

Editor

1.00

0

13/03/2025

Farmacéutica

Sanidad

Economía

Start-up

Biología

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Fuente

H. Lundbeck A/S

Editor

1.00

0

10/03/2025

Farmacéutica

Sanidad

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Fuente

H. Lundbeck A/S

Editor

1.00

0

Seguidores

0

Compatibilidad

0